Skip to main content
. Author manuscript; available in PMC: 2017 Feb 15.
Published in final edited form as: J Immunol. 2016 Jan 15;196(4):1443–1448. doi: 10.4049/jimmunol.1501634

Table II. EAE severity of RR-EAE mice.

The percentages of mice receiving anti-CD99 or control IgG with no clinical score, mild (score 1–2) or severe disease (score 3–5).

Peak
Treatment No clinical score Mild (1–2) Severe (3–5)
Control IgG 10% (4/40) 35% (14/40) 55% (22/40)
Anti-CD99 25% (10/40) 62.5% (25/40) 12.5% (5/40)
Relapse
Treatment No clinical score Mild (1–2) Severe (3–5)
Control IgG 11% (2/18) 83% (15/18) 6% (1/18)
Anti-CD99 50% (9/18) 50% (9/18) 0% (0/18)